Molecular mechanism of miRNA regulating PD-L1 expression

被引:0
作者
Zhao, Wenxin [1 ,2 ]
Li, Xiaolan [1 ,2 ]
Ren, Qunli [1 ,2 ]
Wang, Qian [1 ,2 ]
Liao, Chengcheng [2 ]
Ding, Tianhao [2 ]
Li, Ping [1 ]
Liu, Jianguo [2 ]
机构
[1] Zunyi Med Univ, Microbial Resources & Drug Dev Key Lab Guizhou Ter, Sch Stomatol, Zunyi 563000, Peoples R China
[2] Zunyi Med Univ, Sch Clin Med, Zunyi 563000, Peoples R China
来源
GENE REPORTS | 2023年 / 31卷
关键词
PD-L1; miRNA; Immune checkpoint; Molecular regulation; Tumor suppressor gene; BREAST-CANCER; TARGETS PD-L1;
D O I
10.1016/j.genrep.2023.101763
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
PD-L1 (programmed death-ligand 1) binding to PD-1 (programmed cell death protein 1) reduces the proliferation of PD-1-positive cells, inhibits their cytokine secretion, and induces apoptosis. miRNA (microRNA) as an important regulator of gene expression, affects the performance of gene function. Similarly, the expression of PDL1 is also regulated by miRNA. miRNAs usually negatively regulate gene expression, however, is there positive regulation? We reviewed the molecular mechanisms of the positive and negative regulation of PD-L1 expression by miRNAs. miRNAs mainly indirectly and positively regulate PD-L1 expression through the regulation of tumor suppressor genes PTEN (phosphatase and tensin homolog) and LATS2 (large tumor suppressor kinase 2), oncogene YAP1 (Yes1 associated transcriptional regulator), DNA damage response protein Ku80 (80-kilodalton subunit of the Ku heterodimer protein), etc., while negative regulation is mainly achieved by miRNAs directly binding to the 3 & PRIME;-UTR (3 & PRIME; untranslated region) of PD-L1 mRNA. And this negative regulation can also be reversed by the negative regulation of miRNAs by RNA-binding protein LIN28 (protein lin-28) or circRNAs (circular RNA) such as cire0000284 and circ-CPA4. The revealing of this mechanism provides more references and strategies for immune checkpoint therapy of tumors.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] An alternatively spliced PD-L1 isoform PD-L1Δ3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response
    Dioken, Didem Naz
    Ozgul, Ibrahim
    Yilmazbilek, Irem
    Yakicier, Mustafa Cengiz
    Karaca, Ezgi
    Erson-Bensan, Ayse Elif
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023,
  • [42] An alternatively spliced PD-L1 isoform PD-L1△3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response
    Dioken, Didem Naz
    Ozgul, Ibrahim
    Yilmazbilek, Irem
    Yakicier, Mustafa Cengiz
    Karaca, Ezgi
    Erson-Bensan, Ayse Elif
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (12) : 4065 - 4075
  • [43] Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
    Rosemarie Tremblay-LeMay
    Nasrin Rastgoo
    Hong Chang
    [J]. Journal of Hematology & Oncology, 11
  • [44] Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
    Tremblay-LeMay, Rosemarie
    Rastgoo, Nasrin
    Chang, Hong
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [45] HER-3 molecular classification, expression of PD-L1 and clinical importance in breast cancer
    Stanek, Libor
    Gurlich, Robert
    Whitley, Adam
    Petra, Tesarova
    Music, Zdenek
    Novakova, Lucie
    [J]. BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2022, 123 (10): : 719 - 723
  • [46] PD-L1 and PD-L2 expression in colorectal cancer
    Zeynep, Ozgul
    Funda, Canaz
    Evrim, Yilmaz
    Deniz, Arik
    Bulent, Yildiz
    Fatih, Yasar. N.
    [J]. INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2023, 66 (01) : 31 - 37
  • [47] PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment
    Dimitrios Mathios
    Jacob Ruzevick
    Christopher M. Jackson
    Haiying Xu
    Sagar Shah
    Janis M. Taube
    Peter C. Burger
    Edward F. McCarthy
    Alfredo Quinones-Hinojosa
    Drew M. Pardoll
    Michael Lim
    [J]. Journal of Neuro-Oncology, 2015, 121 : 251 - 259
  • [48] PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment
    Mathios, Dimitrios
    Ruzevick, Jacob
    Jackson, Christopher M.
    Xu, Haiying
    Shah, Sagar
    Taube, Janis M.
    Burger, Peter C.
    McCarthy, Edward F.
    Quinones-Hinojosa, Alfredo
    Pardoll, Drew M.
    Lim, Michael
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2015, 121 (02) : 251 - 259
  • [49] What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1
    Palicelli, Andrea
    Croci, Stefania
    Bisagni, Alessandra
    Zanetti, Eleonora
    De Biase, Dario
    Melli, Beatrice
    Sanguedolce, Francesca
    Ragazzi, Moira
    Zanelli, Magda
    Chaux, Alcides
    Canete-Portillo, Sofia
    Bonasoni, Maria Paola
    Soriano, Alessandra
    Ascani, Stefano
    Zizzo, Maurizio
    Castro Ruiz, Carolina
    De Leo, Antonio
    Giordano, Guido
    Landriscina, Matteo
    Carrieri, Giuseppe
    Cormio, Luigi
    Berney, Daniel M.
    Gandhi, Jatin
    Nicoli, Davide
    Farnetti, Enrico
    Santandrea, Giacomo
    Bonacini, Martina
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (22)
  • [50] Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test
    Yuan, Keyu
    Wu, Jiangping
    Zhao, Yanjie
    Lyu, Shuzhen
    Zhou, Quan
    Shi, Feng
    Li, Yanping
    Song, Qingkun
    [J]. DIAGNOSTIC PATHOLOGY, 2022, 17 (01)